Earnings call Ventas posted 10% YoY normalized FFO per share growth in Q3 2025, driven by 16% SHOP NOI growth and raised full-year guidance again. The company expects 9% FFO growth and 7.5% same-store ...
A potential novel therapeutic target for invasive soft tissue sarcoma detected through tumor immune microenvironment and genetic profile analyses. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results